EFFICACY OF ORAL DEFERASIROX BY TWICE-DAILY DOSING IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SALEHIFAR EBRAHIM; KARAMI HOSSEIN; KOSARYAN MEHRNOOSH; MASOUDI HOSEIN; ALIASGHARIAN AILY; MOUSAVI MASOUMEH; AVAN RAZIEH

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download Full-Text

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

View:

767

Download:

Cites:

Information Journal Paper

Title

EFFICACY OF ORAL DEFERASIROX BY TWICE-DAILY DOSING IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA

Author(s)

Keywords

BETA THALASSEMIA MAJORQ3

DEFERASIROXQ2

FERRITINQ3

TWICE-DAILYQ2

EFFICACYQ2

Abstract

Background and purpose: Patients with BETA THALASSEMIA MAJOR need consistent blood transfusion from early years of life. DEFERASIROX is used as an oral chelating agent (once daily) to excrete excess iron. This study aimed to compare the EFFICACY of DEFERASIROX twice daily and the usual once daily dosing.Materials and methods: This before after clinical trial was performed in 2013-2014 in patients who were at least 2 years of age and received only DEFERASIROX as the chelating agent. All patients had received DEFERASIROX for at least six month once daily. The last FERRITIN before entering the study and the mean DEFERASIROX daily dose during the previous six months were considered as baseline FERRITIN and DEFERASIROX dose, respectively. Laboratory tests were performed including CBC-diff, serum FERRITIN, Creatinine (Cr), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) to evaluate the EFFICACY and safety of DEFERASIROX.Results: A total of 21 transfusion-dependent patients (mean age: 21±6 years old) were included of whom 67% were male. The mean FERRITIN level decreased significantly from 1814±922 ng/ml to 1472±907 ng/ml (P=0.02). There were no any significant changes in AST, ALT and Cr levels compared to baseline values.Conclusion: Twice daily dosing of DEFERASIROX was associated with more decrease in FERRITIN level compared to baseline single daily dose values without any hepatic or renal adverse effects.

Cites

No record.

References

No record.

Cite

APA: Copy

SALEHIFAR, EBRAHIM, KARAMI, HOSSEIN, KOSARYAN, MEHRNOOSH, MASOUDI, HOSEIN, ALIASGHARIAN, AILY, MOUSAVI, MASOUMEH, & AVAN, RAZIEH. (2015). EFFICACY OF ORAL DEFERASIROX BY TWICE-DAILY DOSING IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA. JOURNAL OF MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES, 25(129), 1-8. SID. https://sid.ir/paper/44862/en

Vancouver: Copy

SALEHIFAR EBRAHIM, KARAMI HOSSEIN, KOSARYAN MEHRNOOSH, MASOUDI HOSEIN, ALIASGHARIAN AILY, MOUSAVI MASOUMEH, AVAN RAZIEH. EFFICACY OF ORAL DEFERASIROX BY TWICE-DAILY DOSING IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA. JOURNAL OF MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES[Internet]. 2015;25(129):1-8. Available from: https://sid.ir/paper/44862/en

IEEE: Copy

EBRAHIM SALEHIFAR, HOSSEIN KARAMI, MEHRNOOSH KOSARYAN, HOSEIN MASOUDI, AILY ALIASGHARIAN, MASOUMEH MOUSAVI, and RAZIEH AVAN, “EFFICACY OF ORAL DEFERASIROX BY TWICE-DAILY DOSING IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA,” JOURNAL OF MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES, vol. 25, no. 129, pp. 1–8, 2015, [Online]. Available: https://sid.ir/paper/44862/en

Related Journal Papers